Ionis Pharmaceuticals and Ono Pharmaceutical announced a global license agreement for sapablursen in polycythemia vera in March 2025.

Meanwhile, Sapablursen (ONO-0530), developed by Ono Pharmaceutical, introduces an antisense oligonucleotide strategy targeting thrombopoietin receptor mRNA.

Strategic partnerships with Biogen, GSK, and Sobi, as well as licensing income from deals like the $280 million sapablursen contract, support Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS ...

Strategic partnerships with Biogen, GSK, and Sobi, as well as licensing income from deals like the $280 million sapablursen contract, support Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS ...

Discover Ionis Pharmaceuticals' stellar Q1 2025 earnings: TRYNGOLZA's strong debut, raised revenue guidance, and strategic milestones propel growth.

Oppenheimer has maintained an Outperform rating on Ionis with a price target of $78, noting a recent partnership with Ono Pharmaceuticals to develop sapablursen for polycythemia vera.